Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension

European Journal of Pharmacology

Volumn 575, Issue 1-3, 2007, Pages 105-112

  Llorens, Silvia ^a   Mendizabal, Yolanda ^a   Nava, Eduardo ^a  

^a University of Castilla La Mancha   (Spain)

Author keywords

Endothelium; Glitazones; Hypertension

Indexed keywords

ACETYLCHOLINE; GLITAZONE DERIVATIVE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PIOGLITAZONE; PROSTANOID; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA MEDIA; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEREDITARY HYPERTENSION; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ACETYLCHOLINE; ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HYPERTENSION; INDOMETHACIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PROSTAGLANDINS; RATS; RATS, INBRED SHR; THIAZOLIDINEDIONES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 35348909692     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.002     Document Type: Article

References (28)

1. Asano M., Nakajima T., Iwasawa K., Morita T., Nakamura F., Imuta H., Chisaki K., Yamada N., Omata M., and Okuda Y. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br. J. Pharmacol. 128 (1999) 673-683
2. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., and Hsueh W.A. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96 (1995) 354-360
3. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 52-57
4. Cho D.H., Choi Y.J., Jo S.A., and Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J. Biol. Chem. 279 (2004) 2499-2506
5. Diep Q.N., El M.M., Cohn J.S., Endemann D., Amiri F., Virdis A., Neves M.F., and Schiffrin E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 (2002) 2296-2302
6. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
7. Dubey R.K., Zhang H.Y., Reddy S.R., Boegehold M.A., and Kotchen T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 265 (1993) R726-R732
8. Fujiwara T., Ohsawa T., Takahashi S., Ikeda K., Okuno A., Ushiyama S., Matsuda K., and Horikoshi H. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sci. 63 (1998) 2039-2047
9. Goud C., Pitt B., Webb R.C., and Richey J.M. Synergistic actions of insulin and troglitazone on contractility in endothelium-denuded rat aortic rings. Am. J. Physiol. 275 (1998) E882-E887
10. Grinsell J.W., Lardinois C.K., Swislocki A., Gonzalez R., Sare J.S., Michaels J.R., and Starich G.H. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am. J. Hypertens. 13 (2000) 370-375
11. Hall J.E., Summers R.L., Brands M.W., Keen H., and Alonso-Galicia M. Resistance to metabolic actions of insulin and its role in hypertension. Am. J. Hypertens. 7 (1994) 772-788
12. Hulman S., Falkner B., and Chen Y.Q. Insulin resistance in the spontaneously hypertensive rat. Metabolism 40 (1991) 359-361
13. Koshinaka K., Oshida Y., Han Y.Q., Ohsawa I., and Sato Y. The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats. Metabolism 53 (2004) 22-27
14. Kotchen T.A., Zhang H.Y., Reddy S., and Hoffmann R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am. J. Physiol. 270 (1996) R660-R666
15. Krieter P.A., Colletti A.E., Doss G.A., and Miller R.R. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab. Dispos. 22 (1994) 625-630
16. Llorens S., Salazar F.J., and Nava E. Assessment of the nitric oxide system in the heart, aorta and kidney of aged Wistar-Kyoto and spontaneously hypertensive rats. J. Hypertens. 23 (2005) 1507-1514
17. Majithiya J.B., Paramar A.N., and Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc. Res. 66 (2005) 150-161
18. Martens F.M., Visseren F.L., Lemay J., de Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
19. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin. Ther. 26 (2004) 177-190
20. Moroe H., Fujii H., Honda H., Arai K., Kanazawa M., Notoya Y., and Kogo H. Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. Eur. J. Pharmacol. 497 (2004) 317-325
21. Nicol C.J., Adachi M., Akiyama T.E., and Gonzalez F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18 (2005) 549-556
22. Ogihara T., Rakugi H., Ikegami H., Mikami H., and Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8 (1995) 316-320
23. Peuler J.D., Miller J.A., Bourghli M., Zammam H.Y., Soltis E.E., and Sowers J.R. Disparate effects of antidiabetic drugs on arterial contraction. Metabolism 46 (1997) 1199-1205
24. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
25. Tao L., Liu H.R., Gao E., Teng Z.P., Lopez B.L., Christopher T.A., Ma X.L., Batinic-Haberle I., Willette R.N., Ohlstein E.H., and Yue T.L. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 108 (2003) 2805-2811
26. Verma S., Bhanot S., Arikawa E., Yao L., and McNeill J.H. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 56 (1998) 7-16
27. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., and Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47 (1998) 810-814
28. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118